Company: PTPI
Filing Date: 2025-02-13
Form Type: S-1/A
Source: 0001410578-25-000122
Chunk: 194

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: S-1/A
Chunk 194
---
 of the Compensation Committee has been an officer or employee of the Company. None of our executive officers serves on the board of directors or compensation committee of a company that has an executive officer that serves on our Board or Compensation Committee.

113

PRINCIPAL STOCKHOLDERS The following table sets forth information with respect to the beneficial ownership of our voting securities as of February 6, 2025, by each stockholder known by us to be the beneficial owner of more than 5% of our voting securities and each of our directors and named executive officers. We have determined beneficial ownership in accordance with the rules of the SEC, which generally means that a person has beneficial ownership of a security if he or she possesses sole or shared voting or investment power of that security, including options that are currently exercisable or are exercisable within 60 days of February 6, 2025. Unless otherwise indicated, to our knowledge, the persons and entities named in the table below have sole voting and sole investment power with respect to all shares that they beneficially own, subject to community property laws where applicable. The information in the table below does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Sections 13(d) and 13(g) of the Securities Act. We have based our calculation of the percentage of beneficial ownership prior to this offering on 11,319,039 shares of our common stock outstanding as of February 6, 2025 and 567.85 shares of Series A Preferred Stock outstanding as of February 6, 2025, convertible into 252,378 shares of common stock. We have based our calculation of the percentage of beneficial ownership after this offering on 85,668,481 shares of our common stock outstanding immediately after the closing of this offering, which further reflects the issuance of 74,349,442 shares of common stock in this offering and assumes no sale of any Pre-Funded Warrants and assumes none of the Series Warrants or shares of Series B Preferred Stock issued in this offering are exercised or converted, respectively. The table below does not give effect to the issuance of the Stock Awards in the amount of 2,200,000 shares of restricted shares of common stock to be issued to certain directors and officers of the Company, subject to the closing of this offering. Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o Petros Pharmaceuticals, Inc., 1185 Avenue of the Americas, 3rd Floor, New York, NY